Editas Medicine Announces First Quarter 2022 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Editas Medicine (EDIT) PT Lowered to $15 at Stifel
May 4, 2022 3:53 PM EDTStifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $19.00) while maintaining a Hold rating.
The analyst commented, "No changes to our thesis pending clarity on the therapeutic profile of EDIT-101 (Leber congenital amaurosis type 10 [LCA10])... More
Editas Medicine (EDIT) Tops Q1 EPS by 5c
May 4, 2022 6:51 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.74), $0.05 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $3.85 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More